BEONE MEDICINES - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

or completeness of this announcement, and expressly expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by such content.

BeOne Medicines Ltd. BeiGene Co., Ltd.

(Company incorporated under Swiss law) (Stock code: 06160)

Overseas regulatory announcement

This announcement is made by BeOne Medicines Ltd. (the "Company") pursuant to the Hong Kong Joint Stock Exchange Made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities of Hong Kong Limited.

This is to set forth the Company’s “2025 Capital Raising of BeiGene Co., Ltd.” published on the website of the Shanghai Stock Exchange. Special Report on Cash Deposits and Actual Usage" "China International Capital Corporation, Goldman Sachs (China) Securities Co., Ltd. regarding the storage and use of funds raised by BeiGene Co., Ltd. in 2025

Verification Opinions" and "Ernst & Young Hua Ming LLP (Special General Partnership) Regarding BeiGene Co., Ltd. Special Report on the Storage and Use of Raised Funds in 2025" is for reference only.

By order of the board of directors BeiGene Co., Ltd.

Chairman Mr. Olejian

Hong Kong, April 15, 2026

As at the date of this announcement, the Company’s Board of Directors includes Mr. Ou Leiqiang, Chairman and Executive Director, and Non-executive Directors Dr. Wang Xiaodong, as well as independent non-executive directors Dr. Olivier Brandicourt and Margaret Han Dugan Dr. Michael Goller, Anthony C. Hooper, Ranjeev Krishana,

Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, Ms. Shalini Sharp and Mr. Yi Qingqing.

A share code: 688235 A share abbreviation: BeiGene Announcement number: 2026-009

Hong Kong stock code: 06160 Hong Kong stock abbreviation: BeiGene

US stock code: ONC

BeiGene Co., Ltd.

Special report on the deposit and actual use of raised funds each year 2025 sue

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.

or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

1. Basic information on raising funds

(1) Actual amount of funds raised and fund arrival status

According to the "About Agreeing to BeiGene Corporation" issued by the China Securities Regulatory Commission on November 16, 2021,

Co., Ltd.’s Initial Public Offering of Stocks Registration Approval” (China Securities Regulatory Commission License [2021] No. 3568), BeiGene

Zhouzhou Co., Ltd. (hereinafter referred to as the "Company") made its initial public offering of RMB ordinary shares (A shares) (to

(hereinafter referred to as the "Issuance") 115,055,260 shares, the issuance price per share is RMB 192.60, and the funds raised

The total amount of funds raised was RMB 22,159,643,100; the net amount of funds raised after deducting issuance expenses was RMB

21,630,154,900 yuan. The above-mentioned raised funds have all been received on December 8, 2021, Ernst & Young Hua Ming Accountants

The firm (special general partnership) reviewed the company’s receipt of funds raised from this issuance, and

On December 8, 2021, the Ernst & Young Hua Ming (2021) Capital Verification Report No. 61119809_A03 was issued.

After the raised funds are received, all funds have been deposited in a fund-raising fund approved by the company's board of directors or the audit committee of the board of directors.

Raise funds in a special account.

(2) Use and balance of raised funds

As of December 31, 2025, the company had used raised funds of RMB 21,209.63 million in total.

The use and balance of funds raised by the company are as follows:

Basic information on raised funds

Unit: thousand yuan Currency: RMB

Initial public offering of RMB ordinary shares in 2021 (A Issue name shares) stocks The time for receipt of raised funds is December 8, 2021

This reporting period is from January 1, 2025 to December 31, 2025

Item Amount Total funds raised 22,159,643 Including: Amount of excess raised funds 1,630,155

Less: Direct payment of issuance expenses 520,578 minus: Amount used in previous years 17,920,231 Amount used during the year 3,289,396

Add: Interest income from raised funds, net of handling fees 593,307 Balance of raised funds at the end of the reporting period 1,022,745

2. Management of raised funds

(1) Management system of raised funds

In order to standardize the management and use of funds raised by the company, improve the efficiency and effectiveness of fund use, and protect the rights of investors

In accordance with the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and the "Shanghai Stock Exchange Science and Technology Innovation Board"

Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations" and other relevant laws, regulations, rules and normative

According to the provisions of the document, combined with the company's articles of association and the actual situation of the company, the "BeiGene Co., Ltd. A-share offering

Fund Raising Management System" (hereinafter referred to as the "A Share Raising Fund Management System"), for A share raising funds

Specific and clear regulations have been made on storage, use, management and supervision.

(2) Supervision agreement on raised funds

According to the above-mentioned laws, regulations, rules and normative documents and the company's "A-share raised funds management system"

According to the requirements, the company has cooperated with the joint sponsors China International Capital Corporation Limited and Goldman Sachs Gaohua Securities Co., Ltd.

The liability company (Goldman Sachs Gaohua Securities Co., Ltd. has now been renamed "Goldman Sachs (China) Securities Co., Ltd.

The company") and the commercial bank where the raised funds are deposited have signed a corresponding special account storage supervision agreement for raised funds.

(3) Storage status of raised funds in special account

As of December 31, 2025, the company's deposit balance of raised funds is as follows:

Raised funds storage status table Unit: thousand yuan Currency: RMB

2021 IPO People's Issue name Coin ordinary shares (A shares) stocks The time for receipt of raised funds is December 8, 2021 balance at the end of the reporting period Account name Opening bank Bank account number Account status Um BeOneMedicines Ltd (. Former Industrial Bank Shanghai Branch NRA21620010 3 in use Called "BEIGENE, LTD.") Bank Sales Department 0116888888 BeiGene (Shanghai) Biotech Industrial Bank Shanghai Branch 216200100103

• In use Technology Co., Ltd. Sales Department 074596 BeiGene (Shanghai) Biotech Industrial Bank Shanghai Branch 216200100103 144,609 in use Technology Co., Ltd. Sales Department 081183 BeiGene (Shanghai) Biotech Industrial Bank Shanghai Branch 216200100103
• In use Technology Co., Ltd. Sales Department 080149 BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100108
• In use Company Sales Department 966663 BeiGene (Shanghai) Biomedical Industrial Bank Shanghai Branch 216200100103
• In use Pharmaceutical Technology Co., Ltd. Sales Department 011102 BeiGene (Beijing) Biotech Industrial Bank Shanghai Branch 216200100103 219,610 in use Technology Co., Ltd. Sales Department 002729 BeiGene (Guangzhou) Innovation Technology Industrial Bank Shanghai Branch 216200100105 2,597 in use Technology Co., Ltd. Sales Department 777776 BeiGene (Suzhou) Biotech Industrial Bank Shanghai Branch 216200100103 39,310 in use Technology Co., Ltd. Sales Department 008233 Beijing Yingren Weiye Biotechnology Industrial Bank Shanghai Branch 216200100103
• In use Co., Ltd. Sales Department 003765 BeiGene (Shanghai) Pharmaceutical Research Industrial Bank Shanghai Branch 216200100103 10,055 in use Development Co., Ltd. Sales Department 011332 BeiGene (Guangzhou) Pharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100106 46 in use Co., Ltd. Sales Department 299991 Guangzhou BeiGene Biopharmaceutical Industrial Bank Shanghai Branch 216200100106 166,105 in use Co., Ltd. Sales Department 288882 BeiGene (Beijing) Biotech Industrial Bank Shanghai Branch 216200100107 14 in use Technology Co., Ltd. (Capital) Business Department 166668

BeiGene (Suzhou) Biotech Industrial Bank Shanghai Branch 216200100123 118,474 in use Technology Co., Ltd. (Capital) Business Department 166668 BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100116 8,169 in use Company (Capital) Bank Sales Department 966660 Guangzhou BeiGene Biopharmaceuticals China Merchants Bank Co., Ltd. 120912347310 Co., Ltd. Guangzhou Branch 608 313,753 In use Sales Department BeiGene (Suzhou) Biological Science and Technology Co., Ltd. China Merchants Bank Co., Ltd. 512907215710 Technology Co., Ltd. (Capital) Co., Ltd. Guangzhou Branch 222 - In use Sales Department Guangzhou BeiGene Biopharmaceutical Industrial Bank Shanghai Branch 216200100108

• In use Co., Ltd. Shanghai Branch Sales Department 989389 Total 1,022,745 /

3. Actual use of funds raised this year

(1) Usage of raised funds for investment projects

For details on the actual use of the company's raised funds in 2025, please see "Appendix 1: Comparison of the Use of Raised Funds".

(2) Advance investment and replacement of fundraising projects

During the reporting period, the company had no prior investment or replacement in fundraising projects.

(3) Temporarily supplementing working capital with idle raised funds

During the reporting period, the company did not use idle raised funds to temporarily replenish working capital.

(4) Cash management of idle raised funds and investment in related products

During the reporting period, the company did not conduct cash management or invest in related products with idle raised funds.

(5) Use of excess raised funds to permanently supplement working capital or return bank loans

During the reporting period, the company did not use excess raised funds to permanently replenish working capital or repay bank loans.

situation. As of December 31, 2025, the company has used a total of RMB 1,467 million of super-raised funds for permanent

Replenish working capital.

Detailed list of usage of excess raised funds

Unit: thousand yuan Currency: RMB

Issuance name 2021 initial public offering of RMB ordinary shares (A shares)

The time for receipt of raised funds is December 8, 2021

Method of use Amount of use Date of review and approval by the board of directors

Permanent replenishment of working capital 489,000 November 12, 2024 Permanent replenishment of working capital 489,000 November 10, 2023 Permanent replenishment of working capital 489,000 April 27, 2022

(6) The excess raised funds will be used for projects under construction and new projects (including acquisition of assets, etc.) or to repurchase the company.

Shares and cancellation

The company's board of directors reviewed and approved the "Using Super Raised Funds to Increase Fundraising for Investment Projects" on November 11, 2025.

Proposal to Raise Capital Investment and Extend Project Implementation Period", agreeing that the company will use the remaining excess raised funds in RMB

163,154,860 yuan to increase the planned investment amount of funds raised in the "drug clinical trial research and development project". In view of the fact that the company intends to

Increase the investment in raised funds for "drug clinical trial research and development projects", and combine the implementation status of the projects with

On the premise that the subject and implementation methods of the project will not change, the "drug clinical trial research and development" of the raised investment project will be

The implementation period of the project has been extended to December 31, 2026.

The company’s joint sponsors are China International Capital Corporation and Goldman Sachs (China) Securities Co., Ltd.

The company issued the "China International Capital Corporation Limited and Goldman Sachs (China) Securities Co., Ltd.

BeiGene Co., Ltd. uses excess raised funds to increase investment in raised funds and extend project implementation

Verification Opinions on Deadline”.

Detailed list of usage of excess raised funds (used for projects under construction and new projects)

Unit: thousand yuan Currency: RMB

Issuance Name 2021 Initial Public Offering of RMB Ordinary Shares (A Shares)

The time for receipt of raised funds is December 8, 2021

Planned investment and over-raising were reviewed and approved by the board of directors Project name Project type Total investment Funding Amount Date Drug Clinical Trials November 11, 2025 Projects under construction 15,280,700 163,155 R&D project day (7) Usage of surplus raised funds

During the reporting period, the company did not use any surplus funds from raised investment projects for other raised investment projects or non-raised investment projects.

purpose situation.

4. Changes in the use of funds for investment projects

During the reporting period, the company did not change the use of funds for fundraising projects.

5. Problems in the use and disclosure of raised funds

During the reporting period, the company has timely and

The relevant information of the raised funds was truly, accurately and completely disclosed, and there were no important matters regarding the use of the raised funds.

Big violation situation.

6. Attestation report issued by an accounting firm on the deposit and use of funds raised annually by the company

concluding observations

Ernst & Young Hua Ming LLP (Special General Partnership) reviewed the deposit and placement of funds raised by the company in 2025

The usage has been verified and the "Storage and Actual Usage of Funds Raised by BeiGene Co., Ltd." has been issued.

Special Report" (Ernst & Young Hua Ming (2026) Special No. 70033281_A02). After verification, accountants Ernst & Young Hua Ming LLP (Special General Partnership) believe that: BeiGene has

Co., Ltd.’s special report on raised funds is in accordance with the “Supervisory Rules for Raised Funds of Listed Companies”,

"Self-regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations" and related standards

The formal guide is compiled to truthfully reflect the deposit and actual use of funds raised by BeiGene Co., Ltd. in 2025.

situation.

7. Special report issued by the joint sponsor on the storage and use of funds raised by the company in 2025

Concluding observations on the verification report

After verification, the joint sponsors China International Capital Corporation Limited and Goldman Sachs (China) Securities Co., Ltd.

The responsible company believes that: the deposit and use of funds raised by the company in 2025 are in compliance with the provisions of the Shanghai Stock Exchange

Rules for the Listing of Stocks on the Science and Technology Innovation Board", "Regulations on the Supervision of Funds Raised by Listed Companies", "Shanghai Stock Exchange Science and Technology Innovation Board"

Municipal Company Self-Regulation Guidelines No. 1 - Standardized Operations" and "A-Share Raised Funds Management System" and other laws

In accordance with the provisions of laws and regulations and institutional documents, the company has carried out special account storage and special use of the raised funds, and has fulfilled the requirements in a timely manner. The relevant information disclosure obligations were fulfilled and there was no illegal use of raised funds.

Announcement is hereby made.

BeiGene Co., Ltd. Board of Directors

April 15, 2026

Schedule 1:

Comparison table of usage of raised funds Unit: thousand yuan Currency: RMB

Issuance name 2021 initial public offering of RMB ordinary shares (A shares) Date of receipt of raised funds: December 8, 2021 The total amount of raised funds invested this year was 3,289,396 The total amount of raised funds invested is 21,209,627

Total amount of raised funds changed use - Proportion of total raised funds changed use - As of the end of the period The deadline for the project is Changed cumulative investment project can Commitment to investment projects, final investment, scheduled Projects, including the accumulated amount and commitment as of the end of the period, are they feasible this year? Raised investment projects Raised funds commitment Adjusted investment Investment progress this year Available for use Hechao raised capital investment Partial change Commitment investment Estimated investment amount Commitment investment realized to expected Whether it will happen Nature Total investment amount Total deposit amount (%) Status date Change to (such as Amount (1) (2) The difference in amount (4) = period (specific benefits Benefits Significant changes Yes) (3)＝ (2)/(1) to month) (2)-(1) internal sub drug clinical trials R&D project Project adjustment 13,245,940 13,409,095 13,409,095 3,075,312 13,120,822 -288,273 97.85 Not applicable Not applicable Not applicable No R&D projects whole R&D center construction R&D projects None 467,700 467,700 467,700 2,940 488,681 20,981* 104.49* Completed Not applicable Not applicable No Project Production base research and development Production and construction None 150,000 150,000 150,000 - 153,451 3,451* 102.30* Completed Not applicable Not applicable No and industrialization projects Marketing network construction Operation management None 136,360 136,360 136,360 - 143,560 7,200* 105.28* Completed Not applicable Not applicable No

Project supplementary flow Supplementary working capital None 6,000,000 6,000,000 6,000,000 211,144 5,836,113 -163,887 97.27 Not applicable Not applicable Not applicable No funds supplementary flow Over-raised funds None 1,630,155 1,467,000 1,467,000 - 1,467,000 - 100.00 Not applicable Not applicable Not applicable No funds Total 21,630,155 21,630,155 21,630,155 3,289,396 21,209,627 -420,528 98.06 — — — — Reasons for not meeting the planned progress (depending on specific fundraising projects) Not applicable. Description of significant changes in project feasibility Not applicable. Preliminary investment and replacement of investment projects with raised funds During the reporting period, there was no early investment and replacement of investment projects with raised funds. Use of idle raised funds to temporarily replenish working capital During the reporting period, there was no use of idle raised funds to temporarily replenish working capital.

Cash management of idle raised funds and investment in related products During the reporting period, there was no cash management and investment in related products of idle raised funds. During the reporting period, the company did not use excess raised funds to permanently replenish working capital or repay bank loans. As of December 31, 2025 Use super-raised funds to permanently supplement working capital or return bank loans On the same day, the company used a total of RMB 1,467 million of super-raised funds to permanently replenish working capital. As of December 31, 2025, in addition to the R&D center construction project, production base R&D and industrialization project and marketing network construction project, The amount of the balance of raised funds and the reasons for its formation Except for completion, the raised funds corresponding to other committed investment projects this year are still in the process of investment, and there is no balance of raised funds. On November 11, 2025, the company's board of directors reviewed and approved the "Using Super Raised Funds to Increase Raised Capital Investment in Raised Investment Projects and Extend the Project "Proposal on Project Implementation Period", agreeing that the company will use the remaining excess raised funds of RMB 163,154,860 to increase "drug clinical trial research and development projects" Other uses of raised funds The amount of raised funds is planned to be invested, and in view of the company's plan to increase the investment of raised funds in the "drug clinical trial research and development project", combined with the project's Implementation situation, on the premise that the implementation entity and implementation method of the raised investment project will not change, the "drug clinical trial research and development" of the raised investment project will be The implementation period of the project has been extended to December 31, 2026.

• The cumulative investment amount in the R&D center construction project, production base R&D and industrialization project and marketing network construction project is greater than the committed investment amount, and the excess amount belongs to the interest income of the raised funds.

China International Capital Corporation, Goldman Sachs (China) Securities Co., Ltd.

About BeiGene, Inc.

Verification opinions on the storage and use of raised funds in 2025

China International Capital Corporation Limited and Goldman Sachs (China) Securities Co., Ltd. (hereinafter collectively referred to as the "Joint

"BeiGene Sponsor") is publicly disclosed for the first time as BeiGene, Inc. (hereinafter referred to as "BeiGene" or the "Company").

A joint sponsor institution that issues RMB ordinary shares (A shares) and is listed on the Science and Technology Innovation Board, according to the Shanghai Stock Exchange

Stock Exchange's Science and Technology Innovation Board Stock Listing Rules" "Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on Science and Technology Innovation Board" No. 1 - Standardized Operations", "Supervisory Rules for Fund Raising by Listed Companies" and other relevant regulations, regarding BeiGene

The storage and use of funds raised in 2025 have been carefully reviewed. The details are as follows:

1. Basic information on raising funds

(1) Actual amount of funds raised and fund arrival status

According to the "Concerning Agreement with BeiGene" issued by the China Securities Regulatory Commission on November 16, 2021,

Approval of the Registration for the Initial Public Offering of Stocks by a State Co., Ltd. (China Securities Regulatory Commission License [2021] No. 3568), Baidu

Jishenzhou's initial public offering of RMB ordinary shares (A shares) (hereinafter referred to as the "Issuance")

115,055,260 shares, the issuance price per share is RMB 192.60, and the total amount of funds raised is RMB 22,159,643,100 yuan; the net amount of funds raised after deducting issuance expenses was RMB 21,630,154,900 yuan.

The above-mentioned raised funds have all been received on December 8, 2021. Ernst & Young Hua Ming LLP (Special General Accounting Firm)

Tong Partnership) reviewed the company’s availability of funds raised from this issuance, and on December 8, 2021

On the same day, the Ernst & Young Hua Ming (2021) Capital Verification Report No. 61119809_A03 was issued. Raised funds to After accounting, all have been deposited in the special fund-raising fund approved by the company’s board of directors or the audit committee of the board of directors.

within the account.

(2) Use and balance of raised funds

As of December 31, 2025, the company had used a total of RMB 21,209.63 million in raised funds. public

The use and balance of funds raised by the company are as follows:

Basic information on raised funds

Unit: thousand yuan Currency: RMB

Initial public offering of RMB ordinary shares (A shares) in 2021 Issue name stocks The time for receipt of raised funds is December 8, 2021

This reporting period is from January 1, 2025 to December 31, 2025

Item Amount

Total funds raised 22,159,643 Including: Amount of excess raised funds 1,630,155 Less: Direct payment of issuance expenses 520,578

minus: Amount used in previous years 17,920,231 Amount used during the year 3,289,396

Add: Interest income from raised funds, net of handling fees 593,307 Balance of raised funds at the end of the reporting period 1,022,745

2. Management of raised funds

(1) Management system of raised funds

In order to standardize the management and use of funds raised by the company, improve the efficiency and effectiveness of fund use, and protect the rights of investors In accordance with the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and the "Shanghai Stock Exchange Science and Technology Innovation Board"

Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operations" and other relevant laws, regulations, rules and normative

According to the provisions of the document, combined with the company's articles of association and the company's actual situation, the "BeiGene Co., Ltd. A-share offering

Fund Raising Management System" (hereinafter referred to as the "A Share Raising Fund Management System"), for A share raising funds Specific and clear regulations have been made on the storage, use, management and supervision of gold.

(2) Supervision agreement on raised funds

In accordance with the requirements of the above-mentioned laws, regulations, rules and normative documents and the "Management System for Funds Raised by A Shares"

According to the request, the company has signed the corresponding special fund-raising agreement with the joint sponsor and the commercial bank where the raised funds are deposited.

User storage supervision agreement.

(3) Storage status of raised funds in special account

As of December 31, 2025, the company's deposit balance of raised funds is as follows:

Raised funds storage status table Unit: thousand yuan Currency: RMB 2021 IPO People's Issue name Coin ordinary shares (A shares) stocks The time for receipt of raised funds is December 8, 2021

balance at the end of the reporting period Account name Opening bank Bank account number Account status Um BeOne Medicines Ltd (. Former Industrial Bank Shanghai Branch NRA21620010 3 in use Called "BEIGENE, LTD.") Sales Department: 0116888888 BeiGene (Shanghai) Biotech Industrial Bank Shanghai Branch 216200100103

• In use Technology Co., Ltd. Sales Department 074596 BeiGene (Shanghai) Biotech Industrial Bank Shanghai Branch 216200100103 144,609 in use Technology Co., Ltd. Sales Department 081183 BeiGene (Shanghai) Biotech Industrial Bank Shanghai Branch 216200100103
• In use Technology Co., Ltd. Sales Department 080149 BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100108
• In use Company Sales Department 966663 BeiGene (Shanghai) Biomedical Industrial Bank Shanghai Branch 216200100103
• In use Pharmaceutical Technology Co., Ltd. Sales Department 011102 BeiGene (Beijing) Biotech Industrial Bank Shanghai Branch 216200100103 219,610 in use Technology Co., Ltd. Sales Department 002729 BeiGene (Guangzhou) Innovation Technology Industrial Bank Shanghai Branch 216200100105 2,597 in use Technology Co., Ltd. Sales Department 777776 BeiGene (Suzhou) Biotech Industrial Bank Shanghai Branch 216200100103 39,310 in use Technology Co., Ltd. Sales Department 008233 Beijing Yingren Weiye Biotechnology Industrial Bank Shanghai Branch 216200100103
• In use Co., Ltd. Sales Department 003765 BeiGene (Shanghai) Pharmaceutical Research Industrial Bank Shanghai Branch 216200100103 10,055 in use Development Co., Ltd. Sales Department 011332 BeiGene (Guangzhou) Pharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100106 46 in use Co., Ltd. Sales Department 299991 Guangzhou BeiGene Biopharmaceutical Industrial Bank Shanghai Branch 216200100106 166,105 in use Co., Ltd. Sales Department 288882 BeiGene (Beijing) Biotech Industrial Bank Shanghai Branch 216200100107 14 in use Technology Co., Ltd. (Capital) Business Department 166668 BeiGene (Suzhou) Biotech Industrial Bank Shanghai Branch 216200100123 118,474 in use Technology Co., Ltd. (Capital) Business Department 166668 BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100116 8,169 in use Company (Capital) Bank Sales Department 966660

Guangzhou BeiGene Biopharmaceuticals China Merchants Bank Co., Ltd. 120912347310 Co., Ltd. Guangzhou Branch 608 313,753 In use Sales Department

BeiGene (Suzhou) Biological Science and Technology Co., Ltd. China Merchants Bank Co., Ltd. 512907215710 Technology Co., Ltd. (Capital) Co., Ltd. Guangzhou Branch 222 - In use Sales Department

Guangzhou BeiGene Biopharmaceutical Industrial Bank Shanghai Branch 216200100108

• In use Co., Ltd. Shanghai Branch Sales Department 989389 Total 1,022,745 /

3. Actual use of funds raised this year

(1) Usage of funds for investment projects with raised funds (hereinafter referred to as "raised investment projects")

For details on the actual use of the company's raised funds in 2025, please see "Appendix 1: Comparison of the Use of Raised Funds".

(2) Advance investment and replacement of investment projects

During the reporting period, the company had no prior investment or replacement in fundraising projects.

(3) Temporarily supplementing working capital with idle raised funds During the reporting period, the company did not use idle raised funds to temporarily replenish working capital.

(4) Cash management of idle raised funds and investment in related products

During the reporting period, the company did not conduct cash management or invest in related products with idle raised funds.

(5) Use of excess raised funds to permanently supplement working capital or return bank loans

During the reporting period, the company did not use excess raised funds to permanently replenish working capital or repay bank loans.

As of December 31, 2025, the company has used a total of RMB 1,467 million of super-raised funds for permanent Replenish working capital.

Detailed list of usage of super-raised funds

Unit: thousand yuan Currency: RMB

Issuance name 2021 initial public offering of RMB ordinary shares (A shares)

The time for receipt of raised funds is December 8, 2021

Method of use Amount of use Date of review and approval by the board of directors

Permanent replenishment of working capital 489,000 November 12, 2024

Permanent replenishment of working capital 489,000 November 10, 2023 Permanent replenishment of working capital 489,000 April 27, 2022

(6) The excess raised funds will be used for projects under construction and new projects (including acquisition of assets, etc.) or for repurchasing company shares and cancel the situation

The company's board of directors reviewed and approved the "Using Super Raised Funds to Increase Fundraising for Investment Projects" on November 11, 2025.

Proposal to Raise Capital Investment and Extend Project Implementation Period", agreeing that the company will use the remaining excess raised funds in RMB

163,154,860 yuan to increase the planned investment amount of funds raised in the "drug clinical trial research and development project". In view of the fact that the company intends to

Increase the investment in raised funds for "drug clinical trial research and development projects", and combine the implementation status of the projects with

On the premise that the subject and implementation methods of the project will not change, the "drug clinical trial research and development" of the raised investment project will be

The implementation period of the project has been extended to December 31, 2026.

The company’s joint sponsors are China International Capital Corporation and Goldman Sachs (China) Securities Co., Ltd.

The company issued the "China International Capital Corporation Limited and Goldman Sachs (China) Securities Co., Ltd.

BeiGene Co., Ltd. uses excess raised funds to increase investment in raised funds and extend project implementation

Verification Opinions on Deadline”.

Detailed list of usage of excess raised funds (used for projects under construction and new projects)

Unit: thousand yuan Currency: RMB Issuance name 2021 initial public offering of RMB ordinary shares (A shares)

The time for receipt of raised funds is December 8, 2021

Planned investment exceeds the amount raised. The date of review and approval by the board of directors Project name Project type Total investment Funding amount period drug clinical trials Projects under construction 15,280,700 163,155 November 11, 2025 R&D projects

(7) Usage of surplus raised funds

During the reporting period, the company did not use any surplus funds from raised investment projects for other raised investment projects or non-raised investment projects. purpose situation.

4. Changes in the use of funds for investment projects

During the reporting period, the company did not change the use of funds for fundraising projects.

5. Problems in the use and disclosure of raised funds

During the reporting period, the company has disclosed information in accordance with the requirements of applicable laws, regulations, rules and normative documents.

Information related to raised funds, and there are no major violations in the use of raised funds.

6. Attestation issued by an accounting firm regarding the storage and use of funds raised by the company in 2025

concluding observations of the report

Ernst & Young Hua Ming LLP (Special General Partnership) reviewed the deposit and placement of funds raised by the company in 2025

The usage has been verified and the "Storage and Actual Usage of Funds Raised by BeiGene Co., Ltd." has been issued.

Special Report" (Ernst & Young Hua Ming (2026) Special No. 70033281_A02).

After verification, accountants Ernst & Young Hua Ming LLP (Special General Partnership) believe that: BeiGene has

Co., Ltd.’s special report on raised funds is in accordance with the “Supervisory Rules for Raised Funds of Listed Companies”,

"Self-regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations" and related standards

The formal guide is compiled to truthfully reflect the deposit and actual use of funds raised by BeiGene Co., Ltd. in 2025.

situation.

7. Special report issued by the joint sponsor on the storage and use of funds raised by the company in 2025

Concluding observations on the verification report

After verification, the joint sponsor believes that: the company’s deposit and use of funds raised in 2025 are in compliance with

"Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" "Supervisory Rules for Fund Raising by Listed Companies" "Shanghai

Self-regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Stock Exchange No. 1 - Standardized Operations" and "A-Share Raising Funds"

In accordance with the provisions of laws, regulations and institutional documents such as the Fund Management System, the company has carried out special account storage and storage of raised funds. It has been used for special purposes and relevant information disclosure obligations have been fulfilled in a timely manner. There is no illegal use of raised funds.

(No text below)

Schedule 1:

Comparison table of usage of raised funds

Unit: thousand yuan Currency: RMB

Issuance name 2021 initial public offering of RMB ordinary shares (A shares)

Date of receipt of raised funds: December 8, 2021

The total amount of raised funds invested this year was 3,289,396

The total amount of raised funds invested is 21,209,627

Total amount of raised funds changed use -

Proportion of total raised funds changed use -

By the end of the period, the project reached Changed deadline The accumulated investment can reach the scheduled project Committed investment project project, no investment yet As of the end of the period, the accumulated amount and commitments as of the end of the period are feasible for the current year. Raised investment projects include part of the raised capital commitment. Adjusted investment. Investment progress this year. Hechao raised capital investment. Commitment investment. Total investment amount. Commitment investment status date. Achieved to expected. Whether to occur. towards Nature changes (changes) Such as Total investment amount Total amount Amount(1) Deposit amount (2) The difference in amount ((4%)＝) period (effective and significant changes) (3)＝(2)- from body to moon Yes) (2)/(1) (1) serving) internal sub drug clinical trials R&D project Project adjustment 13,245,940 13,409,095 13,409,095 3,075,312 13,120,822 -288,273 97.85 Not applicable Not applicable Not applicable No R&D projects whole Construction of R&D center R&D projects None 467,700 467,700 467,700 2,940 488,681 20,981* 104.49* Completed Not applicable Not applicable No

Project

Production base research and development Production and construction None 150,000 150,000 150,000 - 153,451 3,451* 102.30* Completed Not applicable Not applicable No and industrialization projects Marketing network construction Operation management None 136,360 136,360 136,360 - 143,560 7,200* 105.28* Completed Not applicable Not applicable No Project

supplementary flow Supplementary working capital None 6,000,000 6,000,000 6,000,000 211,144 5,836,113 -163,887 97.27 Not applicable Not applicable Not applicable No funds supplementary flow Over-raised funds None 1,630,155 1,467,000 1,467,000 - 1,467,000 - 100.00 Not applicable Not applicable Not applicable No funds Total 21,630,155 21,630,155 21,630,155 3,289,396 21,209,627 -420,528 98.06 — — — —

Reasons for not meeting the planned progress (depending on specific fundraising projects) Not applicable.

Description of significant changes in project feasibility Not applicable.

Preliminary investment and replacement of investment projects with raised funds During the reporting period, there was no early investment and replacement of investment projects with raised funds.

Use of idle raised funds to temporarily replenish working capital During the reporting period, there was no use of idle raised funds to temporarily replenish working capital.

Cash management of idle raised funds and investment in related products During the reporting period, there was no cash management and investment in related products of idle raised funds.

During the reporting period, the company did not use excess raised funds to permanently replenish working capital or repay bank loans. As of December 31, 2025, the company has accumulated Use super-raised funds to permanently supplement working capital or return bank loans The excess raised capital of RMB 1,467 million was used to permanently replenish working capital.

As of December 31, 2025, in addition to the completion of the R&D center construction project, production base R&D and industrialization project and marketing network construction project, this year The amount of the balance of raised funds and the reasons for its formation The raised funds corresponding to other committed investment projects are still in the process of being invested, and there is no balance of raised funds.

On November 11, 2025, the company's board of directors reviewed and approved the "Proposal to Use Super Raised Funds to Increase Raised Capital Investment in Raised Investment Projects and Extend the Project Implementation Period." Case", it was agreed that the company would use the remaining excess raised funds of RMB 163,154,860 to increase the planned investment amount of the raised funds for the "Drug Clinical Trial Research and Development Project", and Other uses of raised funds As the company plans to increase investment in raised funds for "drug clinical trial research and development projects", based on the implementation of the project, the implementation entities and implementation methods of the raised investment projects will be different. Subject to changes, the implementation period of the "Drug Clinical Trial Research and Development Project" of the raised investment project will be extended to December 31, 2026.

• The cumulative investment amount in the R&D center construction project, production base R&D and industrialization project and marketing network construction project is greater than the committed investment amount, and the excess amount belongs to the interest income of the raised funds.

BeiGene Co., Ltd.

2025

Special report on the storage and actual use of raised funds

Directory

Pages

1. Attestation report on the storage and actual use of raised funds 1 - 2

2. Special report on the storage and actual use of raised funds 3 – 10

Attestation report on the storage and actual use of raised funds

Ernst & Young Hua Ming (2026) Special No. 70033281_A02

BeiGene Co., Ltd.

BeiGene Co., Ltd. Board of Directors:

We accept the entrustment to review the attached storage and actual use of funds raised by BeiGene Co., Ltd. in 2025. The special report ("Special Report on Raised Funds") was attested. In accordance with the "Regulations on the Supervision of Funds Raised by Listed Companies", "Shanghai Stock Exchange's Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations" and related format guides Prepare a special report on raised funds and ensure that its content is true, accurate and complete, and does not contain false records or misleading statements. Any statements or material omissions are the responsibility of the Board of Directors of BeiGene, Inc. Our responsibility is based on performing the assurance work

The company issued an independent assurance opinion on the special report on raised funds.

We follow the "Chinese Certified Public Accountants Standards for Other Assurance Engagements No. 3101 - Audit or Review of Historical Financial Information" The assurance engagement was performed in accordance with the provisions of "Assurance Engagements Other than Review". The standard requires us to plan and perform assurance work to Obtain reasonable assurance as to whether there are no material misstatements in the special report on raised funds. During the attestation process, we implemented packages Including understanding, random inspection, verification and other procedures we deem necessary. We believe that our assurance work is published Opinions provide a sound basis.

We believe that the special report on funds raised by BeiGene Co., Ltd. complies with the "Public Fund Raising of Listed Companies" in all material aspects. Fund Raising Supervision Rules", "Shanghai Stock Exchange's Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations" "Work" and related format guides have been compiled to truthfully reflect the deposit and actual placement of funds raised by BeiGene Co., Ltd. in 2025.

Usage.

This report is only used by BeiGene Co., Ltd. to disclose its 2025 annual report and is not suitable for other purposes.

A member firm of Ernst & Young Global Limited

Attestation report on the storage and actual use of raised funds (continued)

Ernst & Young Hua Ming (2026) Special No. 70033281_A02

BeiGene Co., Ltd.

(This page has no text)

Ernst & Young Hua Ming LLP (Special General Partnership) Chinese Certified Public Accountant: Yang Kaihua

Chinese Certified Public Accountant: Sun Zhangpu

Beijing, China April 13, 2026

A member firm of Ernst & Young Global Limited

BeiGene Co., Ltd. Special report on the storage and actual use of raised funds

2025

1. Basic information on raising funds

(1) Actual amount of funds raised and fund arrival status

According to the "About Agreeing to BeiGene Co., Ltd." issued by the China Securities Regulatory Commission on November 16, 2021

Approval of the Registration of the Company’s Initial Public Offering of Stocks" (China Securities Regulatory Commission License [2021] No. 3568), BeiGene Co., Ltd. (hereinafter referred to as the "Company") initial public offering of RMB ordinary shares (A shares) (hereinafter referred to as the "Issuance") 115,055,260 shares, the issuance price per share is RMB 192.60, and the total amount of funds raised is RMB 2,215,964.31

million; the net amount of funds raised after deducting issuance expenses was RMB 21,630,154,900. The above raised funds have been raised in On December 8, 2021, everything was in place. Ernst & Young Hua Ming LLP (Special General Partnership) issued a The receipt of the raised funds was reviewed, and the Ernst & Young Hua Ming (2021) Verification Certificate was issued on December 8, 2021. "Capital Verification Report" No. 61119809_A03. After the raised funds are received, all funds have been deposited in the company's board of directors or directors.

The special account for raised funds approved by the Audit Committee shall be opened.

(2) Use and balance of raised funds

As of December 31, 2025, the company has used a total of RMB 21,209.63 million in raised funds. The usage and balance status are as follows:

Basic information on raised funds

Unit: thousand yuan Currency: RMB

Issuance Name 2021 Initial Public Offering of RMB Ordinary Shares (A shares) stocks The time for receipt of raised funds is December 8, 2021 This reporting period is from January 1, 2025 to December 31, 2025 Item Amount Total funds raised 22,159,643 Including: Amount of excess raised funds 1,630,155

Less: Direct payment of issuance expenses 520,578 minus: Amount used in previous years 17,920,231 Amount used during the year 3,289,396 Add: Interest income from raised funds, net of handling fees 593,307 Balance of raised funds at the end of the reporting period 1,022,745

BeiGene Co., Ltd. Special report on the storage and actual use of raised funds

2025

2. Management of raised funds

(1) Management system of raised funds

In order to standardize the management and use of funds raised by the company, improve the efficiency and effectiveness of fund use, and protect the rights and interests of investors, the company In accordance with the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and the "Shanghai Stock Exchange Science and Technology Innovation Board Listed Companies Self-Discipline"

Supervisory Guideline No. 1 - Standardized Operations" and other relevant laws, regulations, rules and normative documents, combined with the provisions of the public In light of the company's articles of association and the company's actual situation, the "BeiGene Co., Ltd. A-share fund raising management system" has been formulated (hereinafter (referred to as "A-share raised funds management system"), the storage, use, management and supervision of A-share raised funds, etc. Specific and clear provisions have been made in each aspect.

(2) Supervision agreement on raised funds

In accordance with the requirements of the above-mentioned laws, regulations, rules and normative documents and the company's "A-share raised funds management system", The company has cooperated with China International Capital Corporation, the joint sponsor, and Goldman Sachs Gaohua Securities Co., Ltd. (Goldman Sachs

Gaohua Securities Co., Ltd. has now been renamed "Goldman Sachs (China) Securities Co., Ltd.") and deposits the raised funds. The financial commercial bank signed the corresponding special account storage supervision agreement for raised funds.

BeiGene Co., Ltd. Special report on the storage and actual use of raised funds

2025

(3) Storage status of raised funds in special account

As of December 31, 2025, the company's deposit balance of raised funds is as follows:

Raised funds storage status table

Unit: thousand yuan Currency: RMB 2021 initial public offering of RMB ordinary Issue name Shares (A shares) stocks The time for receipt of raised funds is December 8, 2021 Bank where the account is opened Bank account number Ending balance of the reporting period Account status Bank name BeOne Medicines Ltd. (formerly known as Industrial Bank Shanghai Branch NRA216200100116888888 3 In use "BEIGENE, LTD.") Sales Department BeiGene (Shanghai) Biotech has the Shanghai branch of Industrial Bank 216200100103074596 - in use Co., Ltd. Bank Sales Department BeiGene (Shanghai) Biotech has the Shanghai branch of Industrial Bank 216200100103081183 144,609 in use Co., Ltd. Bank Sales Department BeiGene (Shanghai) Biotech has the Shanghai branch of Industrial Bank 216200100103080149 - in use Co., Ltd. Bank Sales Department Industrial Bank Shanghai Branch BeiGene Biopharmaceutical Co., Ltd. 216200100108966663 - In use Bank sales department BeiGene (Shanghai) Biomedical Technology Industrial Bank Shanghai Branch 216200100103011102 - in use Technology Co., Ltd. Sales Department BeiGene (Beijing) Biotech has Industrial Bank Shanghai Branch 216200100103002729 219,610 In use Co., Ltd. Bank Sales Department BeiGene (Guangzhou) Innovation Technology has the Shanghai branch of Industrial Bank 216200100105777776 2,597 in use Co., Ltd. Bank Sales Department BeiGene (Suzhou) Biotech has Industrial Bank Shanghai Branch 216200100103008233 39,310 In use Co., Ltd. Bank Sales Department Beijing Yingren Weiye Biotechnology Co., Ltd. Industrial Bank Shanghai Branch 216200100103003765 - in use Company Sales Department BeiGene (Shanghai) Pharmaceutical R&D Co., Ltd. has Industrial Bank Shanghai Branch 216200100103011332 10,055 In use Co., Ltd. Bank Sales Department BeiGene (Guangzhou) Pharmaceuticals Co., Ltd. Industrial Bank Shanghai Branch 216200100106299991 46 in use Company Sales Department Guangzhou BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100106288882 166,105 in use Company Sales Department BeiGene (Beijing) Biotech has Industrial Bank Shanghai Branch 216200100107166668 14 in use Co., Ltd. (capital) Bank Sales Department BeiGene (Suzhou) Biotech has Industrial Bank Shanghai Branch 216200100123166668 118,474 In use Co., Ltd. (capital) Bank Sales Department BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100116966660 8,169 in use (Capital) Bank Sales Department China Merchants Bank Co., Ltd. Guangzhou BeiGene Biopharmaceutical Co., Ltd. Co., Ltd. Guangzhou Branch 120912347310608 313,753 In use Division Sales Department China Merchants Bank Co., Ltd. BeiGene (Suzhou) Biotechnology Co., Ltd. Co., Ltd. Guangzhou Branch 512907215710222 - In use Ltd. (capital) Sales Department Guangzhou BeiGene Biopharmaceutical Co., Ltd. Industrial Bank Shanghai Branch 216200100108989389 - In use Shanghai Branch Sales Department Total 1,022,745

BeiGene Co., Ltd. Special report on the storage and actual use of raised funds

2025

3. Actual use of funds raised this year

(1) Usage of raised funds for investment projects

For details on the actual use of funds raised by the company in 2025, please see "Appendix 1: Comparison of the use of raised funds".

(2) Advance investment and replacement of fundraising projects

During the reporting period, the company had no prior investment or replacement in fundraising projects.

(3) Temporarily supplementing working capital with idle raised funds

During the reporting period, the company did not use idle raised funds to temporarily replenish working capital.

(4) Cash management of idle raised funds and investment in related products

During the reporting period, the company did not conduct cash management or invest in related products with idle raised funds.

(5) Use of excess raised funds to permanently supplement working capital or return bank loans

During the reporting period, the company did not use excess raised funds to permanently replenish working capital or repay bank loans. cut As of December 31, 2025, the company has used a total of RMB 1,467 million of super-raised funds to permanently replenish working capital.

Detailed list of usage of super-raised funds

Unit: thousand yuan Currency: RMB Issuance name 2021 initial public offering of RMB ordinary shares (A shares)

The time for receipt of raised funds is December 8, 2021

Method of use Amount of use Date of review and approval by the board of directors

Permanent replenishment of working capital 489,000 November 12, 2024 Permanent replenishment of working capital 489,000 November 10, 2023 Permanent replenishment of working capital 489,000 April 27, 2022

BeiGene Co., Ltd. Special report on the storage and actual use of raised funds

2025

(6) The excess raised funds will be used for projects under construction and new projects (including the acquisition of assets, etc.) or to repurchase the company’s shares and

sales situation

The company's board of directors reviewed and approved the "Using Super Raised Funds to Increase Raised Funds for Raised Investment Projects" on November 11, 2025. "Proposal to invest capital and extend the project implementation period", agreeing that the company will use the remaining excess raised funds of RMB 163,154,860 Yuan increased the planned investment amount of raised funds for the "Drug Clinical Trial Research and Development Project". In view of the company's plan to conduct "drug clinical trials"

"Increase the investment in raised funds for experimental research and development projects, and combine the implementation status of the projects with the implementation entities and implementation parties of the raised investment projects." On the premise that the formula does not change, the implementation period of the "drug clinical trial research and development project" of the investment project will be extended to 2026

December 31, year. The company’s joint sponsors, China International Capital Corporation and Goldman Sachs (China) Securities Co., Ltd. China International Capital Corporation, Goldman Sachs (China) Securities Co., Ltd. About BeiGene Co., Ltd.

Verification opinions on the company’s use of excess raised funds to increase investment in raised funds and extend the project implementation period.

Detailed list of usage of excess raised funds (used for projects under construction and new projects)

Unit: thousand yuan Currency: RMB Issuance name 2021 initial public offering of RMB ordinary shares (A shares)

The time for receipt of raised funds is December 8, 2021

Plan to invest more than raised funds, approved by the board of directors Project name Project type Total investment Money Amount Date Drug Clinical Trials November 11, 2025 Projects under construction 15,280,700 163,155 R&D project day

(7) Usage of surplus raised funds

During the reporting period, the company did not use any surplus funds from raised investment projects for other raised investment projects or non-raised investment projects. situation.

4. Changes in the use of funds for investment projects

During the reporting period, the company did not change the use of funds for fundraising projects.

5. Problems in the use and disclosure of raised funds

During the reporting period, the company has timely, truthfully and in accordance with the requirements of applicable laws, regulations, rules and normative documents.

Information related to the raised funds was accurately and completely disclosed, and there were no major violations in the use of raised funds.

BeiGene Co., Ltd. Special report on the storage and actual use of raised funds

2025

Schedule 1: Comparison table of usage of raised funds Unit: thousand yuan Currency: RMB

Issuance name 2021 initial public offering of RMB ordinary shares (A shares) Date of receipt of raised funds: December 8, 2021 The total amount of raised funds invested this year was 3,289,396 The total amount of raised funds invested is 21,209,627

Total amount of raised funds changed use - Proportion of total raised funds changed use - By the end of the period, the project reached Deadline The accumulated investment can reach the scheduled project Committed investment items Changed items End of investment As of the end of the period, the accumulated amount and commitments as of the end of the period are usable for this year. Is it feasible? Raised investment projects, including some Raised funds commitment Adjusted investment This year’s investment progress Project Hechao Fund Raising Promise Investment Amount Calculated Investment Amount Promise Investment Status Date Actual